Thiard News@F4F

@newsen.bsky.social

1 week ago

Henlius Achieves Strong Revenue Growth and Innovation Validation in 2025 Results Report Henlius has announced its impressive 2025 annual results, highlighting three consecutive years of profitability, significant revenue growth, and innovation advancements.

Henlius Achieves Strong Revenue Growth and Innovation Validation in 2025 Results Report #China #Shanghai #biotechnology #Henlius #Serplulimab

Thiard News@F4F

@newsen.bsky.social

1 week ago

Henlius Reports Sustained Growth in Revenues and Profits for 2025 In 2025, Henlius announced impressive financial results, marking its third consecutive year of profitability, growing income and profits significantly.

Henlius Reports Sustained Growth in Revenues and Profits for 2025 #China #Shanghai #Henlius #Hanquyou #Serplulimab

Thiard News@F4F

@newsen.bsky.social

1 week ago

Henlius Reports Strong Growth and Market Expansion in 2025 Financial Results Henlius showcases remarkable financial growth in 2025, marking the third consecutive profitable year, with significant success in global market penetration and innovation.

Henlius Reports Strong Growth and Market Expansion in 2025 Financial Results #China #Shanghai #Henlius #Hanquyou #Serplulimab

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Henlius Achieves Record Growth in 2025 with Strong Profitability and Product Innovation Henlius has reported impressive 2025 results with significant revenue growth and sustained profitability, highlighting its innovation in the global biopharma market.

Henlius Achieves Record Growth in 2025 with Strong Profitability and Product Innovation #China #Shanghai #biotech #Henlius #Serplulimab

Thiard News@F4F

@newsen.bsky.social

1 month ago

Eisai and Henlius Secure Exclusive Agreement for Serplulimab in Japan Eisai and Henlius have announced a groundbreaking exclusive licensing deal for the anti-PD-1 antibody Serplulimab in Japan. This agreement is set to enhance cancer treatment options in the region.

Eisai and Henlius Secure Exclusive Agreement for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Thiard News@F4F

@newsen.bsky.social

1 month ago

Eisai and Henlius Strike Exclusive Deal for Serplulimab in Japan Eisai Co. and Henlius Biotech have reached a significant licensing agreement to commercialize the novel anti-PD-1 antibody serplulimab in Japan, enhancing cancer treatment options.

Eisai and Henlius Strike Exclusive Deal for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Thiard News@F4F

@newsen.bsky.social

1 month ago

Eisai and Henlius Join Forces for Innovative Cancer Treatment in Japan Eisai and Henlius have announced a commercial agreement for the anti-PD-1 antibody serplulimab, enhancing cancer treatment options in Japan.

Eisai and Henlius Join Forces for Innovative Cancer Treatment in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Thiard News@F4F

@newsen.bsky.social

1 month ago

Eisai and Henlius Forge Licensing Deal for Serplulimab in Japan Eisai and Henlius have signed an exclusive agreement for the commercialization of the anti-PD-1 drug Serplulimab in Japan, enhancing cancer treatment options.

Eisai and Henlius Forge Licensing Deal for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Thiard News@F4F

@newsen.bsky.social

1 month ago

Eisai and Henlius Collaborate to Bring Serplulimab to Japanese Patients Eisai and Henlius announce a partnership to exclusively commercialize Serplulimab in Japan, a groundbreaking anti-PD-1 antibody targeting unmet medical needs.

Eisai and Henlius Collaborate to Bring Serplulimab to Japanese Patients #Japan #Tokyo #Eisai #Henlius #Serplulimab

Thiard News@F4F

@newsen.bsky.social

2 months ago

Henlius Unveils Ambitious 'Globalization 2.0' Strategy and Innovation Roadmap at JPM 2026 At JPM 2026, Henlius revealed its 'Globalization 2.0' strategy highlighting innovative product launches and focused development plans through 2030.

Henlius Unveils Ambitious 'Globalization 2.0' Strategy and Innovation Roadmap at JPM 2026 #USA #San_Francisco #Henlius #JPM_2026 #Globalization_2.0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Henlius Unveils Ambitious Globalization Strategy and Innovation Roadmap at JPM 2026 At JPM 2026, Henlius outlined its ambitious 'Globalization 2.0' strategy and long-term innovation plan, projecting over 20 global product launches by 2030.

Henlius Unveils Ambitious Globalization Strategy and Innovation Roadmap at JPM 2026 #United_States #San_Francisco #Henlius #JPM_2026 #Globalization_2.0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Dr. Jason Zhu from Henlius to Deliver Keynote at JPM 2026 Conference The J.P. Morgan Healthcare Conference 2026 will feature Dr. Jason Zhu of Henlius as a keynote speaker, highlighting innovation in bio-pharmaceuticals.

Dr. Jason Zhu from Henlius to Deliver Keynote at JPM 2026 Conference #USA #San_Francisco #Henlius #bio-pharmaceuticals #Jason_Zhu

Thiard News@F4F

@newsen.bsky.social

3 months ago

Jason Zhu Invited to Speak at the Renowned JPM Healthcare Conference 2026 Jason Zhu, CEO of Henlius, will deliver a keynote address at the prestigious J.P. Morgan Healthcare Conference in January 2026 in San Francisco.

Jason Zhu Invited to Speak at the Renowned JPM Healthcare Conference 2026 #United_States #healthcare #San_Francisco #Henlius #JPMorgan

Thiard News@F4F

@newsen.bsky.social

3 months ago

Dr. Jason Zhu to Deliver Keynote at 2026 J.P. Morgan Healthcare Conference in San Francisco Dr. Jason Zhu, CEO of Henlius, will speak at the 44th J.P. Morgan Healthcare Conference, highlighting Henlius's innovative advances in biopharma.

Dr. Jason Zhu to Deliver Keynote at 2026 J.P. Morgan Healthcare Conference in San Francisco #USA #San_Francisco #J.P._Morgan #Henlius #Jason_Zhu

Thiard News@F4F

@newsen.bsky.social

3 months ago

Henlius CEO Dr. Jason Zhu to Speak at the 2026 J.P. Morgan Healthcare Conference Dr. Jason Zhu, CEO of Henlius, will deliver a keynote at the J.P. Morgan Healthcare Conference 2026, discussing innovations and future strategies in biopharma.

Henlius CEO Dr. Jason Zhu to Speak at the 2026 J.P. Morgan Healthcare Conference #USA #San_Francisco #Henlius #Dr._Jason_Zhu #JPM_Conference

Thiard News@F4F

@newsen.bsky.social

3 months ago

CEO Dr. Jason Zhu's Keynote Insights at J.P. Morgan Healthcare Conference 2026 At the upcoming J.P. Morgan Healthcare Conference, Dr. Jason Zhu will present Henlius's innovations and strategic vision for the global biopharma landscape.

CEO Dr. Jason Zhu's Keynote Insights at J.P. Morgan Healthcare Conference 2026 #USA #San_Francisco #J.P._Morgan #Henlius #Dr._Jason_Zhu

Thiard News@F4F

@newsen.bsky.social

5 months ago

HANSIZHUANG’s Phase 3 Trial Achieves Key Milestone in Gastric Cancer Treatment Paving Way for Early NDA Submission The Phase 3 trial of HANSIZHUANG for gastric cancer has met its primary endpoint, facilitating an early NDA submission. This breakthrough could reshape treatment strategies.

HANSIZHUANG’s Phase 3 Trial Achieves Key Milestone in Gastric Cancer Treatment Paving Way for Early NDA Submission #China #Shanghai #gastric_cancer #Henlius #HANSIZHUANG

Thiard News@F4F

@newsen.bsky.social

7 months ago

Henlius Reports Flourishing Growth in First Half of 2025, Driven by Overseas Success and Innovation In the first half of 2025, Henlius reported remarkable financial growth, with overseas product profits surging over 200%, driven by innovation.

Henlius Reports Flourishing Growth in First Half of 2025, Driven by Overseas Success and Innovation #China #Shanghai #Innovation #biotechnology #Henlius

Thiard News@F4F

@newsen.bsky.social

9 months ago

HanchorBio and Henlius Forge Strategic Licensing Agreement to Enhance Global Immuno-Oncology Development HanchorBio has announced a significant licensing agreement with Henlius for HCB101, aiming to boost its footprint in immuno-oncology across multiple regions, including Greater China and MENA.

HanchorBio and Henlius Forge Strategic Licensing Agreement to Enhance Global Immuno-Oncology Development #Taiwan #Taipei #Henlius #HanchorBio #HCB101

Thiard News@F4F

@newsen.bsky.social

11 months ago

Henlius 2025 Global R&D Day: Innovating for Future Success Henlius recently celebrated its 2025 World R&D Day, focusing on collaboration and innovative therapies, highlighting significant advancements in cancer treatment.

Henlius 2025 Global R&D Day: Innovating for Future Success #China #Shanghai #Innovation #Henlius #R&D_Day

Thiard News@F4F

@newsen.bsky.social

11 months ago

Henlius R&D Day 2025: Collaboration Drives Global Innovation Strategy Forward Henlius held its 2025 Global R&D Day under the theme 'Collaborate to Create,' showcasing innovative therapies and strategic growth.

Henlius R&D Day 2025: Collaboration Drives Global Innovation Strategy Forward #China #Shanghai #Henlius #Serplulimab #HLX22

Thiard News@F4F

@newsen.bsky.social

11 months ago

Elevating Global Strategies Through Innovation: Henlius' World R&D Day 2025 Celebration Henlius recently held its World R&D Day 2025 focused on fostering innovation to enhance global strategies in biopharmaceutical development. The event highlighted groundbreaking therapies.

Elevating Global Strategies Through Innovation: Henlius' World R&D Day 2025 Celebration #China #Shanghai #Innovation #Henlius #R&D_Day

Thiard News@F4F

@newsen.bsky.social

11 months ago

Henlius 2025 Global R&D Day: A Summit for Innovation and Strategy in Biopharmaceuticals Henlius' 2025 Global R&D Day emphasized collaboration and innovation, showcasing groundbreaking therapies and strategic advancements in biopharmaceuticals.

Henlius 2025 Global R&D Day: A Summit for Innovation and Strategy in Biopharmaceuticals #China #Shanghai #Innovation #biopharmaceuticals #Henlius

Thiard News@F4F

@newsen.bsky.social

11 months ago

Henlius Accelerates Global Biopharma Strategy at 2025 Global R&D Day Henlius recently held its 2025 Global R&D Day, focusing on innovation and collaboration in biopharmaceuticals, showcasing its advanced therapies and growth strategy.

Henlius Accelerates Global Biopharma Strategy at 2025 Global R&D Day #China #Shanghai #Innovation #Henlius #R&D_Day

Thiard News@F4F

@newsen.bsky.social

1 year ago

Henlius Reports Solid Revenue Growth and Significant Profitability in 2024 Annual Results In its 2024 Annual Results, Henlius showcases impressive revenue growth and a net profit increase of over 50%, reflecting robust market performance.

Henlius Reports Solid Revenue Growth and Significant Profitability in 2024 Annual Results #China #Shanghai #biopharmaceuticals #Henlius #Biosimilars

Thiard News@F4F

@newsen.bsky.social

1 year ago

Henlius Biotech's HLX22 Receives Orphan Drug Designation for Gastric Cancer Treatment in the U.S. Shanghai Henlius Biotech announces that the FDA has granted Orphan Drug Designation to HLX22, its promising anti-HER2 antibody, for gastric cancer treatment.

Henlius Biotech's HLX22 Receives Orphan Drug Designation for Gastric Cancer Treatment in the U.S. #China #Shanghai #Henlius #Henlius_Biotech #HLX22

Thiard News@F4F

@newsen.bsky.social

1 year ago

Henlius and Dr. Reddy's Forge Licensing Agreement for HLX15 Expansion Across Europe and the U.S. Henlius partners with Dr. Reddy's Laboratories to expand HLX15, a biosimilar to daratumumab, in Europe and the U.S., enhancing treatment options.

Henlius and Dr. Reddy's Forge Licensing Agreement for HLX15 Expansion Across Europe and the U.S. #China #Shanghai #Henlius #Dr._Reddy's #HLX15

Thiard News@F4F

@newsen.bsky.social

1 year ago

Henlius and Dr. Reddy's Sign Licensing Agreement for HLX15 Expansion in Europe and US Henlius partners with Dr. Reddy's to expand the investigational biosimilar HLX15 in Europe and the US, aiming for better patient treatment options.

Henlius and Dr. Reddy's Sign Licensing Agreement for HLX15 Expansion in Europe and US #China #Shanghai #Henlius #Dr._Reddy's #HLX15

Thiard News@F4F

@newsen.bsky.social

1 year ago

Henlius and Dr. Reddy's Form Strategic Alliance for HLX15 Biosimilar in Europe and U.S. Shanghai Henlius Biotech has announced a licensing agreement with Dr. Reddy's Laboratories for the HLX15 biosimilar, facilitating expansion in Europe and the U.S.

Henlius and Dr. Reddy's Form Strategic Alliance for HLX15 Biosimilar in Europe and U.S. #China #Shanghai #Henlius #Dr._Reddy's #HLX15

Thiard News@F4F

@newsen.bsky.social

1 year ago

Serplulimab Gains European Approval as First-Line Treatment for ES-SCLC Serplulimab has achieved a monumental milestone, becoming the first anti-PD-1 monoclonal antibody approved in the EU for extensive-stage small cell lung cancer treatment.

Serplulimab Gains European Approval as First-Line Treatment for ES-SCLC #China #Shanghai #Henlius #Serplulimab #HANSIZHUANG